Asco 2025 · Posters · Cáncer Gastrointestinal Volver

CÁNCER GASTROINTESTINAL

  • Colorrectal y anal
Nieves Martínez Lago, MD, PhD

Real-world efficacy of trifluridine/tipiracil and bevacizumab combination according to baseline prognostic factors: The BeTAS study.

Nieves Martínez Lago, MD, PhD

Hospital Clínico Universitario e Instituto de Investigación Sanitaria de Santiago de Compostela

playAcceso
Elena Elez, MD, PhD

Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of pembrolizumab (pembro) versus chemotherapy (chemo) in microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC) in the KEYNOTE-177 trial.

Elena Elez, MD, PhD

Vall d´ Hebron University. Hospital and Institute of Oncology (VHIO)

playAcceso
Eduardo Feliciangeli

Clinical and immunopathological evaluation and its comparison with consensus molecular subtypes of colorectal cancer.

Eduardo Feliciangeli

Hospital General Universitario Santa Lucia, Cartagena, Spain.

playAcceso
Una iniciativa científica de: Eco Logo
Clover sgm Logo
Con el patrocinio de: Regeneron Logo